FAM13b Inhibitors
FAM13b inhibitors employ a diverse range of biochemical mechanisms to indirectly diminish the protein's functional activities. Compounds that target the RAF kinase within the MAPK/ERK signaling pathway, or inhibitors of Src family kinases, impact cellular processes such as proliferation and cytoskeletal organization, where FAM13b plays a contributory role. As these pathways are attenuated, the downstream effects can lead to a reduction in FAM13b's activity, although the protein itself is not the direct target of these inhibitors. Similarly, compounds that inhibit PI3K, a pivotal component of the PI3K/Akt signaling pathway, ultimately influence FAM13b function given its involvement in related cell survival and growth mechanisms. The suppression of PI3K/Akt signaling results in an indirect inhibition ofFAM13b's functional activity, since FAM13b is engaged in this pathway and its downstream effects. Inhibition of MEK, either through compounds acting directly on MEK or those that target upstream kinases, also leads to a decrease in the MAPK/ERK pathway's activity. This reduction in signaling pathway activity has implications for FAM13b, which is implicated in MAPK/ERK-mediated processes.
In addition to these mechanisms, the actin cytoskeleton, which is fundamental to cell structure and movement, is another cellular system that indirectly influences FAM13b activity when disrupted. Inhibitors of ROCK kinases, which form part of the regulatory machinery for actin dynamics, can thereby exert an indirect inhibitory effect on FAM13b. Other inhibitors that modulate the Hedgehog signaling pathway also have the potential to reduce FAM13b activity due to the pathway's role in cell proliferation, a process in which FAM13b is implicated. Furthermore, the inhibition of p38 MAPK and JNK, both key players in other branches of the MAPK signaling network, can similarly result in a diminished activity of FAM13b.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
This compound acts as a potent inhibitor of RAF kinase, which is involved in the MAPK/ERK signaling pathway. Disruption of this pathway can influence FAM13b activity, as FAM13b is implicated in signaling cascades related to cell proliferation and survival. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP 2 is an inhibitor of Src family kinases. Given that Src kinases play roles in multiple signaling pathways, including those that regulate cytoskeletal organization, PP 2 can indirectly affect FAM13b function which is associated with actin cytoskeletal regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that impedes the PI3K/Akt signaling pathway. Since FAM13b is involved in pathways related to cell survival and growth, its activity can be indirectly inhibited by the suppression of PI3K/Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which is upstream of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can attenuate the MAPK/ERK signaling, potentially leading to the inhibition of FAM13b activity which is involved in this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK kinases, which are involved in actin cytoskeletal organization. By inhibiting ROCK, Y-27632 can indirectly inhibit FAM13b, which is thought to play a role in cytoskeletal regulation processes. | ||||||
Ciliobrevin D | 1370554-01-0 | sc-507482 | 10 mg | $413.00 | ||
Targets the Hedgehog signaling pathway by inhibiting dynein. Since Hedgehog signaling can regulate processes in which FAM13b is involved, such as cell proliferation, ciliobrevin D might indirectly inhibit FAM13b via this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, which are key components of the MAPK/ERK pathway. Through suppression of this pathway, U0126 can indirectly lead to decreased activity of FAM13b, which is involved in this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK signaling pathways. By obstructing JNK activity, SP 600125 may indirectly decrease FAM13b activity, given the protein's involvement in MAPK-related signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, a protein kinase that is part of the MAPK signaling network. SB 203580's action can affect FAM13b activity indirectly, due to the role of FAM13b in MAPK-mediated cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that can block the PI3K/Akt pathway. As FAM13b is implicated in signaling processes that involve PI3K/Akt, wortmannin's inhibition of this pathway can lead to decreased FAM13b activity. | ||||||